Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials

L. Simpson, Eric; F. Merola, Joseph; I. Silverberg, Jonathan; Reich, Kristian; B. Warren, Richard; Staumont‐Sallé, D.; Girolomoni, Giampiero; Papp, Kim; de Bruin‐Weller, Marjolein; P. Thyssen, Jacob; Zachariae, Rebecca; Olsen, C.K.; Wollenberg, Andreas

doi:10.1111/bjd.21867

Public

Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials

Published in British Journal of Dermatology • Sep 9, 2022

Authors:

Eric L. Simpson

Joseph F. Merola

Jonathan I. Silverberg

Abstract

BACKGROUND: Tralokinumab is a fully human monoclonal antibody that neutralizes the activity of interleukin-13, a key pathogenic driver of atopic dermatitis (AD). Clinical trials including adults with moderate-to-severe AD, of up to 52 weeks' duration, showed tralokinumab was efficacious and well tol...

Subject

Placebo

Medicine

Atopic dermatitis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!